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RESUMO – A alopécia permanente pós-quimioterapia é um efeito adverso raro, classicamente associada a altas doses de qui-
mioterapia sistémica com busulfan para transplante de medula óssea. Recentemente têm sido descritos casos de  alopécia perma-
nente pós-quimioterapia em doentes submetidos a quimioterapia sistémica com taxanos no carcinoma da mama. Na revisão da 
literatura não existem orientações terapêuticas consistentes para esta entidade com impacto importante na qualidade de vida dos 
doentes. Descreve-se o caso de uma doente de 38 anos que desenvolveu alopecia inaugural e permanente após quimioterapia 
com taxanos (docetaxel) para carcinoma da mama, com 2 anos de evolução à data da observação. Após 6 meses de tratamento 
tópico com solução de minoxidil 5%, em regime bidiário, assistiu-se a resposta clínica favorável. Os autores revêm o provável me-
canismo patológico da alopécia permanente pós-quimioterapia, bem como os efeitos do minoxidil tópico no ciclo do cabelo, por 
forma a sustentar este fármaco como opção terapêutica a considerar neste tipo de alopecia. 
PALAVRAS-CHAVE – Alopecia/induzida quimicamente; Alopecia/tratamento Minoxidil; Taxanos.
Case of Permanent Chemotherapy-Induced Alopecia 
with Response to Topical Minoxidil
ABSTRACT – Permanent chemotherapy-induced alopecia is uncommon and has primarily been reported after high-dose busulfan 
chemotherapy in bone marrow transplant patients. Nevertheless, cases of PCIA, after taxane chemotherapy protocols for breast can-
cer, have been recently described. Despite the impact on patients’ quality of life, no consistently effective treatment has been previou-
sly described for taxane-associated permanent chemotherapy-induced alopecia. We herein report a case of a 38-year-old woman 
who presented inaugural and persistent hair loss after completion of adjuvant chemotherapy with taxane (docetaxel) for breast car-
cinoma, 2 years before the present observation. After 6 months of continuous therapy with topical minoxidil solution 5%, twice daily, 
significant hair regrowth was noted. We discuss the pathophysiology of permanent chemotherapy-induced alopecia and the effects 
of minoxidil on hair growth, in order to substantiate topical minoxidil 5% as an option to consider in the therapeutic approach for 
permanent chemotherapy-induced alopecia.
KEYWORDS – Alopecia/chemically induced; Alopecia/therapy; Minoxidil; Taxoids. 
INTRODUCTION 
Chemotherapy induced alopecia is a very common side 
effect of several cancer treatments and is typically reversible 
within 6 months.1 Permanent chemotherapy-induced alope-
cia (PCIA) is uncommon,1 and has primarily been reported 
with busulfan and high-dose cyclophosphamide conditioning 
regimens, given before bone marrow transplantation.2 Never-
theless, cases of PCIA after taxane chemotherapy protocols for 
breast cancer have been recently described,3-5 showing that 
permanent alopecia is not solely linked to high-dose chemo-
therapy regimens.
No consistently effective treatment has previously been 
described for taxane-associated PCIA. Topical minoxil has 
been used in some reports but a refractory course was typi-
cally described.3,5 
CASE REPORT
We report a case of a 38-year-old caucasian woman with 
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a history of breast carcinoma who presented inaugural and 
persistent hair loss after completion of adjuvant chemothera-
py, 2 years before the present observation. A regimen inclu-
ding docetaxel, adriamycin and cyclophosphamide had been 
followed. Her clinical history was otherwise negative, inclu-
ding for androgenetic alopecia (AGA) and she was currently 
having no other medication. Clinical examination showed a 
diffuse alopecia with characteristics of a female pattern an-
drogenetic hair loss (Ludwig II, Sinclair IV) (Fig. 1a). Trichos-
copy revealed hair shaft diameter variability, with a significant 
proportion of vellus hairs (Fig. 1b). The remaining exami-
nation was otherwise normal, namely the nails. Laboratory 
analysis including hormonal levels, VDRL and autoantibodies 
were in the normal range. Treatment with topical minoxidil 
solution 5%, twice daily, produced some improvement. After 6 
months of continuous therapy, significant regrowth of the hair 
was noted both clinically (Fig. 2a) and dermoscopically (Fig. 
2b) with adequate patient satisfaction.
DISCUSSION
The risk of PCIA is related to several factors, including 
the chemotherapeutic agent. We believe that docetaxel was 
responsible for the PCIA in this case, as already suggested 
by other case reports.3-5 The other two agents in this patient’s 
protocol, typically associated with reversible alopecia,6 may 
also have contributed to PCIA. 
The pathophysiology of PCIA remains to be elucidated. 
Currently, however, it seems that chemotherapeutic agents 
share proapoptotic pathways (mainly mediated by p53) that 
selectively target growing cells, and consequently prominen-
tly affect the highly proliferative hair-matrix keratinocytes 
of anagen hair follicles.7,8 This leads to hair-cycle abnor-
malities, often reversible within 6 weeks after cessation of 
chemotherapy. Hair follicle epithelial stem cells are a vital 
progenitor for epithelial lineages within the follicle.7 Throu-
ghout evolution these cells have developed molecular me-
chanisms of chemoresistance to apoptosis which will allow 
the regeneration of follicles several times over throughout 
life, even after great injury from chemotherapy. Neverthe-
less, it seems that the same resistant hair follicle stem cells 
have an increased sensitivity to select agents, such as taxa-
nes. These agents may have the ability to induce stem-cell 
damage leading to PCIA.7 It is also believed that certain 
genetic polymorphisms determine individual susceptibility to 
Figure 1a - Alopecia inaugural after taxane chemotherapy.
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Figure 1b - Tricoscopy corresponding to Figure 1a : hair shaft diame-
ter variability, with a significant proportion of vellus hairs.
Figure 2a - Clinical improvment six months after treatment with topi-
cal minoxidil 5% twice daily.
Figure 2b - Tricoscopy corresponding to Figure 2a: significant re-
growth of the hair; less  hair shaft diameter variability and fewer vellus 
hairs.
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cytotoxic effects of chemotherapy.9 Therefore, PCIA is likely 
multifactorial: the degree of alopecia induced by chemothe-
rapeutic agents may depend on dose, administration regi-
men, patient age, comorbidities, nutritional and hormonal 
status.7 Overall, beyond drug-related specific hair follicle to-
xicity, many other individual factors are implicated, also sha-
red by other forms of non-scarring alopecia, such as AGA.
PCIA and AGA have different etiologies.8 However, clini-
cal features of PCIA seem strikingly similar to that of severe 
AGA.5 The histological picture of taxane-related permanent 
alopecia is consistent in all published reports.3-5
Although the mode of action remains to be fully unders-
tood, topical minoxidil is known to stimulate hair growth, 
and has proven efficacy on AGA.10 In a review, Messenger 
and Rundegren10 suggested that minoxidil acts mainly on 
the hair cycle, causing premature termination of telogen, 
prolonging anagen. They also postulate that irrespective the 
mechanism of action, minoxidil must have effects on cell 
function: cell growth, collagen and prostaglandin synthesis, 
and stimulation of VEGF synthesis. In addition to the effects 
on the hair cycle, minoxidil action on cell function may have 
some benefit on the hair follicle stem cells, which may ex-
plain improved hair regrowth after PCIA observed in our 
patient,.
Regarding the current knowledge of PCIA mechanism 
and the effects of minoxidil on hair growth, we observed a 
significant improvement of the patient’s alopecia, contras-
ting with the usual refractory course described in PCIA. To-
pical minoxidil 5% twice a day may be a safe option to be 
considered in the therapeutic approach of these patients.
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